The launch of new first-in-class products is expected to drive growth in the lupus market at a compound annual growth rate of 10.6%, according to a report by GlobalData.
Titled ‘PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis – Global Drug Forecast and Market Analysis to 2025’, the report covers the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan.
Including systemic lupus erythematosus (SLE) and lupus nephritis (LN), the lupus market is expected to be driven by the launch first-in-class pipeline drugs anifrolumab, Orencia (abatacept), and Lupuzor, as well as therapeutic drugs, atacicept, blisibimod, and voclosporin.
AstraZeneca’s anifrolumab is an anti-interferon monoclonal antibody (mAb) expected to dominate the lupus market with demonstrated efficacy in patients with cutaneous and articular involvement. The drug is expected to acquire a 75% share of all SLE patients and also drive the development of other anti-interferon mAbs.
The report also projects the increase in prevalence of lupus across the 7MM and better awareness of the disease to result in the rise in uptake of lupus medications.
GlobalData healthcare analyst Sebastian S. Gehrke states that anti-malarials, steroids, and other immunosuppressive agents will continue to dominate the market. Gehrke also anticipates biologics to witness an increase in uptake and strengthen their dominance in the market.
A large share of patients still lack access to efficient medication despite the launch of new pipeline drugs. The existing medications available in the market possess undesirable safety profiles. In addition, poor understanding of the etiology of lupus has resulted in a high unmet need of patients.